<DOC>
	<DOCNO>NCT00290966</DOCNO>
	<brief_summary>Phase II : Primary objective : select one 2 test arm ( docetaxel cisplatin , docetaxel cisplatin 5-FU ) , base primarily complete response , advance phase III survival comparison CDDP + 5-FU control arm . Secondary objective : evaluate quantitative qualitative safety profile 2 test group . Phase III : Primary objective : detect statistically significant increase time progression ( TTP ) test arm ( docetaxel plus cisplatin 5-FU ) relative control arm ( cisplatin plus 5-FU ) . Main secondary objective : detect statistically significant increase overall survival ( OS ) test arm ( docetaxel plus cisplatin 5-FU ) relative control arm ( cisplatin plus 5-FU ) . Other secondary objective : compare response rate , time treatment failure , duration response , safety profile , quality life disease-related symptoms.Socio-economic data collect order able perform analysis country necessary .</brief_summary>
	<brief_title>Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin 5-FU Cisplatin Plus 5-FU Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patient 's consent form obtain , sign date begin specific protocol procedure . Gastric adenocarcinoma include adenocarcinoma esophagogastric junction , histologically proven . Measurable and/or evaluable metastatic disease ; single metastatic lesion manifestation disease , cytology histology mandatory . Locally recurrent disease accept provide least one measurable lesion ( e.g . lymph node ) . Performance status Karnofsky index &gt; 70 % . Life expectancy 3 month . Adequate haematological biochemistry parameter No prior palliative chemotherapy , previous adjuvant ( and/or neoadjuvant ) chemotherapy allow 12 month elapse end adjuvant ( neoadjuvant ) therapy first relapse . Pregnant lactating woman . Patients ( M/F ) reproductive potential implementing adequate contraceptive measure . Other tumor type adenocarcinoma ( leiomyosarcoma ; lymphoma ) . Any prior palliative chemotherapy . Prior adjuvant ( and/or neoadjuvant ) chemotherapy first relapse within 12 month end adjuvant ( neoadjuvant ) . Prior treatment taxanes . Prior CDDP adjuvant ( and/or neoadjuvant ) chemotherapy cumulative dose &gt; 300 mg/mÂ² .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>docetaxel</keyword>
	<keyword>stomach neoplasm</keyword>
</DOC>